Section Arrow
AKTX.NASDAQ
- Akari Therapeutics Plc
Quotes are at least 15-min delayed:2026/04/22 05:06 EDT
Pre Market
Last
 --
-- (--)
Bid
3
Ask
6.94
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 5.87
-0.07 (-1.18%)
Day High 
6.46 
Prev. Close
5.94 
1-M High
6.596 
Volume 
25.81K 
Bid
3
Ask
6.94
Day Low
5.87 
Open
5.99 
1-M Low
3.25 
Market Cap 
6.80M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.58 
20-SMA 4.78 
50-SMA 7.5 
52-W High 59.2 
52-W Low 3.25 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
--/-2.40
Enterprise Value
6.80M
Balance Sheet
Book Value Per Share
24.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
Pre Market 0.2415 +0.0447 +22.71%
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
Pre Market 2.4 -0.29 -10.78%
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
Pre Market 0.3271 -0.0116 -3.42%
GERNGeron Corp1.5-0.06-3.85%-- 
Pre Market 1.52 +0.02 +1.33%
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Pre Market 5.5327 -0.4573 -7.63%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.